DMC Group LLC Has $201,000 Position in Pfizer Inc. $PFE

DMC Group LLC cut its position in Pfizer Inc. (NYSE:PFE) by 45.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,292 shares of the biopharmaceutical company’s stock after selling 7,036 shares during the quarter. DMC Group LLC’s holdings in Pfizer were worth $201,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter worth $27,000. North Capital Inc. acquired a new position in Pfizer during the first quarter worth about $28,000. Bayforest Capital Ltd acquired a new position in Pfizer during the first quarter worth about $28,000. Horizon Financial Services LLC acquired a new position in Pfizer during the first quarter worth about $35,000. Finally, WPG Advisers LLC acquired a new position in Pfizer during the first quarter worth about $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Finally, Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.41.

Pfizer Trading Down 0.6%

PFE opened at $26.27 on Wednesday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a fifty day moving average of $24.76 and a 200-day moving average of $24.14. The stock has a market cap of $149.36 billion, a PE ratio of 13.97, a price-to-earnings-growth ratio of 0.86 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the business posted $0.60 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.